JUPITER LIFE LINE HOSP L
JLHL · General/Diversified · NSE
₹1,357
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for JLHL yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
30%
ROE
12.6%
Debt/Equity
0.38
WACC
11.1%
Market Cap
₹8,895 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.9%
Return on capital employed
EV / EBITDA
26.1×
Enterprise multiple
Debt / EBITDA
1.7×
Leverage vs earnings
Interest Coverage
76.4×
EBIT covers interest
Current Ratio
4.51×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
18.9%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
JLHL · last 5 annual periods
ROE
12.6%
ROCE
17.9%
Operating Margin
—
Debt / Equity
0.38×
PE
—
EV / EBITDA
—
Historical Financials
JLHL · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 yfinance | 2023 yfinance | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹733 Cr | ₹893 Cr | ₹1070 Cr | ₹1302 Cr | ₹1500 Cr | +19.6% |
| EBITDA | ₹150 Cr | ₹206 Cr | ₹260 Cr | ₹328 Cr | ₹381 Cr | +26.2% |
| EBIT | — | — | ₹222 Cr | — | — | +0.0% |
| PAT | ₹51.1 Cr | ₹72.9 Cr | ₹177 Cr | ₹192 Cr | ₹194 Cr | +39.6% |
| EPS (diluted) | — | — | ₹28.65 | — | — | +0.0% |
| CFO | ₹137 Cr | ₹117 Cr | ₹115 Cr | ₹267 Cr | ₹268 Cr | +18.2% |
| CapEx | ₹-91.7 Cr | ₹-77.2 Cr | ₹-85.3 Cr | ₹-328 Cr | ₹-502 Cr | — |
| FCF | ₹45.2 Cr | ₹39.9 Cr | ₹29.2 Cr | ₹-60.8 Cr | ₹-234 Cr | — |
| Total Assets | ₹909 Cr | ₹986 Cr | ₹1281 Cr | ₹1905 Cr | ₹2383 Cr | +27.3% |
| Total Debt | ₹495 Cr | ₹469 Cr | ₹0.0 Cr | ₹393 Cr | ₹584 Cr | +4.2% |
| Shareholders' Equity | ₹294 Cr | ₹366 Cr | ₹1169 Cr | ₹1356 Cr | ₹1544 Cr | +51.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
JLHL vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 HCG HCG | — | — | Pending | 1.0% | 569.9× |
JSLL JSLL | — | — | Pending | 33.2% | — |
PARKHOSPS PARKHOSPS | — | — | Pending | 19.2% | — |
 YATHARTH YATHARTH | — | — | Pending | 8.0% | — |
NEPHROPLUS NEPHROPLUS | — | — | Pending | 6.9% | — |
Click a ticker to view its fair-value analysis.
Dividend History
2 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹2.00/sh
Last payout
2025-07-04
₹1.00
Peak payout
₹1.00
Trailing yield
0.07%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of JLHL →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for JLHL →
Compare
Head-to-head with peers
Compare JLHL side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse JLHLNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.